Clinical Trials Logo

Clostridium Difficile clinical trials

View clinical trials related to Clostridium Difficile.

Filter by:

NCT ID: NCT02774382 Recruiting - Clinical trials for Clostridium Difficile

Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections

Start date: May 1, 2017
Phase: Phase 3
Study type: Interventional

The purpose of the study is to investigate if treatment with fecal microbiota transplantation or rectal bacteriotherapy is superior to standard vancomycin in patients with recurrent Clostridium Difficile infections.

NCT ID: NCT02636517 Recruiting - Ulcerative Colitis Clinical Trials

Fecal Microbiome Transplant

Start date: December 2015
Phase: Phase 1
Study type: Interventional

Fecal Microbiota Transplant (FMT) in pediatric patients with recurrent C. Difficile with or without Inflammatory Bowel Disease (IBD) The aims of this study are to determine the safety and efficacy of FMT treatment in pediatric patients with recurrent or moderate to severe C. Difficile without (through an observational study) and with (through a clinical trial) Inflammatory Bowel Disease and to determine the effect of FMT on the gut microbiota through the use of 454 pyrosequencing before and after transplantation in these patients.

NCT ID: NCT02466698 Recruiting - Clinical trials for Clostridium Difficile

Intestinal Lavage for the Treatment of Severe C. Difficile Infections

Start date: August 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Clostridium Difficile infections (CDIs) are treated initially with antibiotic therapy and supportive care, with surgical intervention reserved for patients with significant systemic toxicity or perforation. Severe CDI may be refractory to medical management and require surgical intervention, carrying a mortality of approximately 40%. Mortality associated with CDI increases significantly as the severity of the infection increases. In patients failing medical management, earlier operation is associated with decreased mortality. However, the lack of validated tools to predict the necessity for surgical intervention, combined with the significant morbidity associated with total colectomy significantly reduces the likelihood of patients receiving early surgical intervention. The purpose of the proposed study is to assess the addition of intestinal PEG lavage via nasojejunal tube to usual care in the treatment of adult patients with severe CDI who have no immediate indication for surgical intervention.

NCT ID: NCT02134392 Recruiting - Clinical trials for Clostridium Difficile

Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection

FMT
Start date: December 2013
Phase: Phase 1
Study type: Interventional

C-diff infection often causes belly pain and diarrhea and can be very hard to treat with medicine. One of the possible reasons that C-diff infection is hard to treat is because there is too much "bad" bacteria in the colon. Investigators believe that putting more "good" bacteria into the colon will help fight the "bad" bacteria. We do this by doing a fecal (poop) transplant. Fecal transplant has been done at other hospitals, but not at Nationwide Children's Hospital. Since our Investigators have not done this before, this study will help us learn the best way to do the transplant. Investigators also believe this transplant might help improve symptoms for patients with C-diff.

NCT ID: NCT01973465 Recruiting - Clinical trials for Clostridium Difficile

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis

Start date: September 2013
Phase: N/A
Study type: Interventional

This study was developed in response to the July, 2013 FDA draft guidance regarding FMT for CDI. The weight of the evidence in the literature suggests that FMT is the most effective treatment for ambulatory outpatients affected by recurrent CDI who fail conventional therapy. The anticipated benefits to research patients enrolled in this study include resolution of chronic diarrhea, return of bowel habits and nutritional status to normal, and resolution of chronic recurrent CDI. FMT involves the endoscopic instillation of freshly obtained stool with millions of live bacteria into the recipient's colon by endoscopic lavage. With any endoscopic procedure, there is a risk of perforated viscous. This is very rare, but the risk is increased with severe CDI. The risk of acquisition of communicable enteric or blood borne pathogen appears to be negligible.

NCT ID: NCT00377078 Recruiting - Clinical trials for Clostridium Difficile

Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.

Start date: October 2005
Phase: N/A
Study type: Interventional

Primary objective of this pilot study is to evaluate the effect of recombinant human lactoferrin on the rate of infection with Clostridium difficile in long-term care patients supported by enteral feeding requiring broad spectrum antibiotics.